title: Effect of a patient support program on access to oral therapy for hematologic malignancies.
abstract: OBJECTIVE
  The results of a study assessing the effectiveness of a manufacturer-sponsored assistance program for patients prescribed oral cancer therapies are presented.
  
  
  METHODS
  Rates of dispensing success were evaluated in a random sample of patients (n = 1000) who enrolled in the Celgene Patient Support (CPS) program for assistance obtaining lenalidomide or thalidomide over a two-year period and a control group of patients (n = 1000) who registered to receive the drugs under restricted-distribution protocols but did not receive CPS assistance. The main study outcomes were (1) the proportion of patients who actually received medication and (2) the time from prescription approval to the initial dispensing of medication.
  
  
  RESULTS
  Despite the complex access issues faced by program enrollees, the proportion of CPS participants who received medication (89%) was comparable to the proportion of patients who received medication in the control cohort (91%). The median time from the approval of prescriptions to the initial dispensing of medication was also comparable in the CPS and control groups (eight days versus five days). The study also evaluated the reasons why medication was not dispensed to CPS enrollees in some cases.
  
  
  CONCLUSIONS
  The percentage of patients who were dispensed prescriptions for lenalidomide or thalidomide did not differ significantly between those who were enrolled in a patient assistance program and those who were not. The median time between prescription authorization and first dispensing was comparable among program and nonprogram patients.
authors.affiliation: United BioSource Corporation, Lexington, MA 02420, USA. chris.pashos@unitedbiosource.com
authors.forename: Chris L
authors.initials: CL
authors.lastname: Pashos
authors.forename: Lael S
authors.initials: LS
authors.lastname: Cragin
authors.forename: Zeba M
authors.initials: ZM
authors.lastname: Khan
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D004345:Drug Industry / Q000191:economics / Q000379:methods*; D005260:Female; D006297:Health Services Accessibility; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D019458:Insurance Coverage; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use; D013997:Time Factors; D014481:United States
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide